Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-11-24 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Security Purchase Plan 22 pages 401.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'SHARE PURCHASE PLAN OFFER BOOKLET' and details a Share Purchase Plan (SPP) by Pharmaxis Ltd, including offer dates, eligibility, pricing, and application instructions. It is a detailed offer document for shareholders to purchase additional shares, describing the terms and conditions of the capital raising. This is not a financial report, earnings release, or management discussion, but a capital raising offer document. It is not a brief announcement but a full offer booklet. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2021-11-24 English
Application for quotation of securities - PXS 6 pages 27.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Pharmaxis Ltd. It details the number and type of securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the securities issuance. The content is focused on the listing and quotation of new securities rather than financial results, management changes, or other report types. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2021-11-23 English
Section 708A(5)(e) Notice 1 page 145.2KB
Capital/Financing Update Classification · 95% confidence The document is a Section 708A(5)(e) Notice under the Corporations Act 2001, relating to the issuance of new shares following a share placement. It confirms compliance with disclosure requirements and states that the shares were issued without disclosure under Part 6D.2 of the Corporations Act. The document is an announcement about a capital raising event and share issuance, not a full financial report or detailed financial data. It is short (1713 characters) and serves as a regulatory announcement about capital changes. Therefore, it fits best under Capital/Financing Update (CAP).
2021-11-23 English
Application for quotation of securities - PXS 5 pages 26.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange) for Pharmaxis Ltd. It details the number and type of securities to be quoted, issue dates, and related information. It references previous announcements and Appendix 3B filings, which are typical for new share issues or placements. The document does not contain financial statements, earnings data, or management discussion. It is an announcement related to capital changes, specifically the quotation of new securities issued. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a formal application for quotation, consistent with SHA filings.
2021-11-22 English
Proposed issue of securities - PXS 7 pages 30.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Pharmaxis Ltd regarding a proposed issue of securities under a securities purchase plan. It details the number of securities to be issued, offer conditions, dates, fees, and other related information. The content focuses on the company's capital raising activity through issuing new shares to existing shareholders. There are no financial statements or detailed financial performance data included, and the document is not a report but an announcement of a capital raising event. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (8072 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2021-11-17 English
Placement 3 pages 152.4KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 17 November 2021 announcing a capital raising event by Pharmaxis Ltd, including a placement of shares and a share purchase plan. It details the amount to be raised, the issue price, the timetable for the placement and share purchase plan, and the intended use of funds. The content focuses on fundraising activities and capital structure changes rather than financial results, management changes, or regulatory filings. The document length is 7573 characters, which is sufficient to contain substantive information about the capital raising. There is no indication that this is a full financial report, earnings release, or regulatory filing. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-11-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.